After dichotomizing patients in these three cohorts into ARID1A-high and -low groups, generally, patients who were placed in the ARID1A-low group had higher baseline alpha-fetoprotein (AFP) levels (AFP > 300 ng/mL; cohort 1, 60% vs. 37%, p = 0.001; cohort 2, 45% vs. 19%, p < 0.001) and advanced HCC stage (stage III; cohort 1, 33% vs. 14%, p = 0.011; cohort 2, 34% vs. 26%, p = 0.002; Table S1). This evidence concerns the gene AFP and hepatocellular carcinoma.